NCT04527471View on ClinicalTrials.gov

Pilot Study of Ensifentrine or Placebo Delivered Via pMDI in Hospitalized Patients With COVID-19

PHASE2CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

September 4, 2020

Primary Completion Date

February 15, 2021

Study Completion Date

May 1, 2021

Conditions
Coronavirus InfectionCovid-19SARS-CoV-2
Interventions
DRUG

Ensifentrine Dose 1

Study drug delivered twice daily via pMDI

DRUG

Placebo pMDI

Placebo delivered twice daily via pMDI

Trial Locations (1)

35294

The University of Alabama at Birmingham, Birmingham

All Listed Sponsors
lead

Verona Pharma Inc

INDUSTRY

NCT04527471 - Pilot Study of Ensifentrine or Placebo Delivered Via pMDI in Hospitalized Patients With COVID-19 | Biotech Hunter | Biotech Hunter